Background: The biology of hepatocellular carcinoma remains undiscovered. A lack of early Diagnostic markers and the poor prognosis of HCC attributes to its high morbidity. HCC is the second most frequent cause of cancer incidence and mortality among men in Egypt, the fourth most prevalent cause of death from cancer. HCC is the ninth most frequently diagnosed cancer in femalesLong non‐coding RNAs (lncRNAs) have been confirmed to be key regulators of most cell processes and cancer. lncRNA TUG1 has mainly been focused on cancer, and lncRNA TUG1 can regulate the development of cancers. TUG1 was used as a non-invasive, cost effective, and complementary biomarker in viral hepatitis C and viral hepatitis C-associated hepatocellular carcinoma. The present study aimed to evaluate the role of LncTUG1 in blood of HCC/HCV patients with the aim of identifying a diagnostic biomarker with a valid non‐invasive technique.TUG1 could be new potential biomarkers with a valid

non‐invasive technique, cost effective, and complementary biomarker in viral hepatitis C and viral hepatitis C-associated hepatocellular carcinoma.